Point Therapeutics Company Profile

15:25 EDT 20th March 2019 | BioPortfolio

Point Therapeutics, Inc is a Boston-based biopharmaceutical company dedicated to developing a family of dipeptidyl peptidase (DPP) inhibitors for use in cancer, type 2 diabetes and as vaccine adjuvants. DPPs are enzymes that appear to regulate several different physiological processes including those involved in tumor growth and host responses to cancer, type 2 diabetes, and immune responses to vaccines.


155 Federal Street Fourth Floor
United States of America


Phone: 617-933-2130
Fax: 617-933-2131

News Articles [1015 Associated News Articles listed on BioPortfolio]

Initial public offering nets $80.2mm for TCR2 Therapeutics

Immuno-oncology firm TCR2 Therapeutics Inc. netted $80.2mm through its initial public offering of 5.75mm common shares (including the overallotment) at $15, the mid-point of the company’s $14-16 int...

Nightstar Therapeutics: Sell-Off Is A Great Entry Point For Long-Term Investors

Initial public offering nets $70mm for TCR2 Therapeutics

Immuno-oncology firm TCR2 Therapeutics Inc. netted $70mm through its initial public offering of 5mm common shares at $15, the mid-point of the company’s $14-16 intended range.

Moderna nets $571.1mm in IPO

In its initial public offering on Nasdaq, Moderna Inc. (messenger RNA (mRNA) therapeutics) netted $571.1mm through the sale of 26.3mm shares at $23, the mid-point of its anticipated range.

Prescription Dermatology Therapeutics Market - Global Industry Analysis, Size, Share, Growth, ...

NEW YORK, Oct. 29, 2018 /PRNewswire/ -- Skin is the largest organ of the body, and the first point of contact for microbes and toxins, Read more...

When scientists push people to their tipping point

(Ohio State University) You probably overestimate just how far someone can push you before you reach your tipping point, new research suggests. A new study tilted people backwards in a device and aske...

Oyster Point Pharma to Present at the BIO CEO & Investor Conference

Oyster Point Pharma, Inc., a privately held clinical-stage pharmaceutical company with an initial focus on developing novel therapies for the treatment of Dry Eye Disease, today a...

Sarepta Therapeutics Acquires Myonexus Therapeutics For $165 Million

WASHINGTON (dpa-AFX) - Sarepta Therapeutics Inc. (SRPT), Wednesday said it has exercised its option to acquire Myonexus Therapeutics, a clinical-stage biotechnology company developing transformati...

Drugs and Medications [148 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]


Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [breathe easy therapeutics, inc]


Diclofenac sodium delayed release [cambridge therapeutics technologies, llc]

Diclofenac Sodium

Olopatadine hydrochloride [a-s medication solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [925 Associated PubMed Articles listed on BioPortfolio]

The use of fast photochemical oxidation of proteins coupled with mass spectrometry in protein therapeutics discovery and development.

Structural analysis of protein therapeutics is a challenging task owing to complexities associated with large molecular size and 3D structures. Recent advances in fast photochemical oxidation of prote...

Terahertz communication windows and their point-to-point transmission verification.

Terahertz communication is recognized as a transformational technology that can meet the future demands of point-to-point communication. The study of terahertz atmospheric transmission characteristics...

Excessive outlier removal may result in cut points that are not suitable for immunogenicity assessments.

Cut point determination is an important aspect of immunogenicity assay development. The cut point can be influenced by a myriad of factors. Key among those is the analytical variability of the assay i...

Searching the Roots of Erb's Auscultation Point.

"Erb's point" is the fifth point of auscultation for the heart exam, located in the third intercostal space close to the sternum. It has sometimes been attributed to famous German neurologist Wilhelm ...

Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.

There is mounting evidence supporting the use of biologic therapeutics for the management of noninfectious uveitis (NIU). This review highlights: biologics with documented efficacy in NIU; agents with...

Clinical Trials [1437 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1803 Associated Companies listed on BioPortfolio]

Point Therapeutics

Point Therapeutics, Inc is a Boston-based biopharmaceutical company dedicated to developing a family of dipeptidyl peptidase (DPP) inhibitors for use in cancer, type 2 diabetes and as vaccine adjuvan...

Turning Point Therapeutics, Inc.

Turning Point Therapeutics is a clinical-stage precision oncology company forging a new path for targeted cancer care. Founded in October 2013 by Dr. J. Jean Cui, the lead invento...

Turning Point Therapeutics Inc.

POINT Biomedical

POINT Biomedical is a privately held pharmaceutical company, founded in 1996 to pursue technologies related to imaging and drug delivery. POINT's core technology is based upon an ultrasonically respon...

Point Foundation

Point Foundation (Point) is the nation's largest scholarship-granting organization for lesbian, gay, bisexual and transgender (LGBT) students of merit. Point provides financial support, leadership tra...

More Information about "Point Therapeutics" on BioPortfolio

We have published hundreds of Point Therapeutics news stories on BioPortfolio along with dozens of Point Therapeutics Clinical Trials and PubMed Articles about Point Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Point Therapeutics Companies in our database. You can also find out about relevant Point Therapeutics Drugs and Medications on this site too.

Quick Search


Relevant Topic

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Corporate Database Quicklinks

Searches Linking to this Company Record